Our Management Team

With an understanding that encompasses not only the challenges faced by the healthcare community, but also what it takes to create and activate networks of key resources, our staff stands ready to provide assistance..



Cynthia L. Clark, President

Cindy has been the President of ibiliti since its inception in 2009. She is a serial entrepreneur with over 23 years of experience in the life science and information technology industries. Before joining ibiliti, she was the CEO (and is now a board director) of Sirga Advanced Biopharma, Inc., an infectious disease biopharma company that spun out of NC State University, and NanIO Biosciences, Inc., a cancer nano-theranostic company. Cindy has also held senior management positions with other North Carolina-based life science companies—Phase Bioscience, Inc. and Erimos Pharmaceuticals.

Before moving to North Carolina six years ago, Cindy held senior management positions with MedCases, Inc., CV Therapeutics, Bell Atlantic Internet Solutions-North and Univax Biologics. She has been involved in the management of companies in all stages of development—from start-up to mid-stage to public companies, and has been responsible for fundraising at all levels (seed, venture and public) totaling over $150 million during her career.

In the non-profit sector, she has been actively involved with the organization and administration of many volunteer arts, philanthropy, trade association and economic development organizations.

Cindy holds a J.D. from Washington College of Law and a B.A. with honors in government and mathematics from Wesleyan University.




Dan Deaton, Vice President of Innovation

Dan is a veteran of product development with several successful high growth and entrepreneurial companies. His 14-year career includes RTP-based Magnetic Imaging Technologies (acquired by Nycomed Amersham), Duke technology spin-out, Industrial Microwave Systems, and the publically traded Kos Pharmaceuticals (acquired by Abbott in 2006).

Most recently, Dan was Director of Product Development for Oriel Therapeutics, a venture- backed specialty pharmaceutical company spun out of UNC Chapel Hill. In 2010 Oriel was acquired by Sandoz, the generic division of Novartis. At Oriel, Dan led a diverse team of consultants and engineers that developed the Solis dry powder inhaler platform from conception through commercial readiness.

Dan is a native of North Carolina and has an MBA from the University of North Carolina at Chapel Hill, as well as a Bachelor and Master of Science in Mechanical Engineering from North Carolina State University.